Lifeline for sickle cell patients: drug access extended in new study

NCT ID NCT04657822

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to crizanlizumab, a drug that helps reduce painful crises in sickle cell disease, for 130 patients who benefited from it in earlier Novartis trials. Participants must have completed a prior study and lack other access to the drug. The main goal is to keep providing treatment and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: crizanlizumab (a drug given by IV infusion to reduce pain crises)
What this could lead to: If successful, this study ensures patients with sickle cell disease can keep receiving a treatment that helps control their condition while longer-term access is arranged.
What could go wrong: This is not a test of whether the drug works—it's a continuation study for people already benefiting. Side effects are still possible, and the drug may not be available to everyone long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Augusta University Georgia
RECRUITING

Augusta, Georgia, 30912, United States
Childrens Hospital of Philadelphia
ACTIVE_NOT_RECRUITING

Philadelphia, Pennsylvania, 19104-4399, United States
Childrens National Hospital
ACTIVE_NOT_RECRUITING

Washington D.C., District of Columbia, 20010, United States
Cook Childrens Medical Center
COMPLETED

Fort Worth, Texas, 76104, United States
East Carolina University
COMPLETED

Greenville, North Carolina, 27834, United States
East Carolina University
COMPLETED

Greenville, North Carolina, 27858, United States
Novartis Investigative Site
COMPLETED

Brussels, 1000, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Laken, 1020, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Liège, 4000, Belgium
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Salvador, Estado de Bahia, 41253-190, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Ribeirão Preto, São Paulo, 14051-140, Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

São Paulo, São Paulo, 01232-010, Brazil
Novartis Investigative Site
RECRUITING

Barranquilla, Atlántico, 080020, Colombia
Novartis Investigative Site
RECRUITING

Valledupar, Cesar Department, 200001, Colombia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Cali, Valle del Cauca Department, 760032, Colombia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Montería, 230004, Colombia
Novartis Investigative Site
COMPLETED

Créteil, 94010, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Paris, 75015, France
Novartis Investigative Site
COMPLETED

Paris, 75015, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Padova, PD, 35128, Italy
Novartis Investigative Site
COMPLETED

Orbassano, TO, 10043, Italy
Novartis Investigative Site
RECRUITING

Beirut, 113-0236, Lebanon
Novartis Investigative Site
RECRUITING

Tripoli, 1434, Lebanon
Novartis Investigative Site
RECRUITING

Khoudh, 123, Oman
Novartis Investigative Site
COMPLETED

Barcelona, 08035, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Madrid, 28009, Spain
Novartis Investigative Site
WITHDRAWN

Hatay, Antakya, 31101, Turkey (Türkiye)
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Adana, Saricam, 01330, Turkey (Türkiye)
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Adana, Yuregir, 01250, Turkey (Türkiye)
University Of Alabama
RECRUITING

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.